Biomarkers of pituitary neoplasms

Anticancer Research

Volumn 32, Issue 11, 2012, Pages 4639-4654

  Sav, Aydin ^a   Rotondo, Fabio ^b   Syro, Luis V ^c   Scheithauer, Bernd W ^d   Kovacs, Kalman ^b  

^a ACIBADEM UNIVERSITY   (Turkey)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c HOSPITAL PABLO TOBÓN URIBE   (Colombia)

^d MAYO CLINIC   (United States)

Author keywords

Angiogenesis; Apoptosis; Cox 2; Folliculostellate cells; Galectin 3; Hif 1alpha; Inflammation and tumor; Matrix metalloproteinases (MMPS); Microarray; Microenvironment; Microvessel density (MVD); P27; P53; Pituitary stem cells; Pituitary tumor transforming gene (PTTG); Proliferative marker (ki 67); Review; Topoisomerase 2 alpha; Tumor heterogeneity; VEGF

Indexed keywords

BIOLOGICAL MARKER; CD31 ANTIGEN; CD34 ANTIGEN; CORTICOTROPIN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLOOXYGENASE 2; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE INHIBITOR; FOLLITROPIN; GALECTIN 3; GROWTH HORMONE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; LUTEINIZING HORMONE; MATRIX METALLOPROTEINASE; MICRORNA; PROLACTIN; PROTEIN BAX; PROTEIN P53; SECURIN; THYROTROPIN; VASCULOTROPIN;

3' UNTRANSLATED REGION; ACTH SECRETING ADENOMA; ACTH SECRETING CELL; ANGIOGENESIS; APOPTOSIS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CELL ADHESION; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL DEATH; CELL HETEROGENEITY; CELL PROLIFERATION; CHROMOSOME SEGREGATION; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; DNA HELIX; DNA REPLICATION; DOWN REGULATION; ELECTRON MICROSCOPY; ENZYME ACTIVE SITE; EUKARYOTIC CELL; GENETIC CODE; GONADOTROPIN SECRETING CELL; GROWTH HORMONE SECRETING ADENOMA; GROWTH HORMONE SECRETING CELL; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS CELL; HYPOPHYSIS TUMOR; IMMUNOREACTIVITY; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROLACTIN SECRETING CELL; PROLACTINOMA; REVIEW; SPECTRUM; STELLATE CELL; STEM CELL; TSH SECRETING CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE; TUMOR VOLUME;

HUMANS; PITUITARY NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872697811     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (165)

1. Decock J, Paridaens R and Ye S: Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. Clin Genet 73(3): 197-211, 2008.
2. Bamberger CM, Fehn M, Bamberger AM, Lüdecke DK, Beil FU, Saeger W and Schulte HM: Reduced expression levels of the cell-cycle inhibitor p27KIP1 in human pituitary adenomas. Eur J Endocrinol 140(3): 250-255, 1999.
3. Beaulieu E, Kachra Z, Mousseau N, Delbecchi L, Hardy J and Béliveau R: Matrix metalloproteinases and their inhibitors in human pituitary tumors. Neurosurgery 45(6): 1432-1440, 1999.
4. Fukui S, Nawashiro H, Otani N, Ooigawa H, Yano A, Nomura N, Tokumaru AM, Miyazawa T, Ohnuki A, Tsuzuki N, Katoh H, Ishihara S and Shima K: Vascular endothelial growth factor expression in pituitary adenomas. Acta Neurochir Suppl 86: 519-521, 2003.
5. Hentschel SJ, McCutcheon E, Moore W and Durity FA: p53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Can J Neurol Sci 30(3): 215-219, 2003.
6. Hiyama H, Kubo O, Kawamata T, Ishizaki R and Hori T: Expression of cyclin kinase inhibitor p21/WAF1 protein in pituitary adenomas: Correlations with endocrine activity, but not cell proliferation. Acta Neurochir (Wien) 144(5): 481-488,2002.
7. Bloomer CW, Kenyon L, Hammond E, Hyslop T, Andrews DW, Curran WJ and Dicker AP: Cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) expression in human pituitary macroadenomas. Am J Clin Oncol 26(4): 75-80, 2003.
8. Jin L, Qian X, Kulig E, Sanno N, Scheithauer BW, Kovacs K, Young WF Jr and Lloyd RV: Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27KIP1 expression in nontumorous and neoplastic human pituitaries. Am J Pathol Aug 151(2): 509-519, 1997.
9. Onguru O, Casey MB, Kajita S, Nakamura N and Lloyd RV: Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors: a review. Endocr Pathol 16(4): 253-277, 2005.
10. Thodou E, Argyrakos T and Kontogeorgos G: Galectin-3 as a marker distinguishing functioning from silent corticotroph adenomas. Hormones (Athens) 6(3): 227-232, 2007.
11. Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Fèvre-Montange M, Rey C, Figarella-Branger D, Raverot G, Belin MF, Lachuer J and Trouillas J: A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors: Endocr Relat Cancer 14: 887-900, 2007.
12. Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV and Cusimano M: Biomarkers of pituitary: A review. (Part II). Neurosurgery 67(6): 1790-1798, 2010.
13. Vidal S, Horvath E, Kovacs K, Scheithauer BW, Lloyd RV and Kontogeorgos G: Ultrastructural features of apoptosis in human pituitary adenomas. Ultrastruct Pathol 25(2): 85-92, 2001.
14. Ibrahim AE, Pickering RM, Gawne-Cain ML, King S, Lees PD and Ellison DW: Indices of apoptosis and proliferation as potential prognostic markers in nonfunctioning pituitary adenomas. Clin Neuropathol 23(1): 8-15, 2004.
15. Kulig E, Jin L, Qian X, Horvath E, Kovacs K, Stefaneanu L, Scheithauer BW and Lloyd RV: Apoptosis in nontumorous and neoplastic human pituitaries: expression of the BCL-2 family of proteins. Am J Pathol 54(3): 767-774, 1999.
16. Kontogeorgos G, Sambaziotis D, Piaditis G and Karameris A: Apoptosis in human pituitary adenomas: A morphologic and in situ end-labeling study. Mod Pathol 10(9): 921-926, 1997.
17. Nakabayashi H, Sunada I and Hara M: Immunohistochemical analyses of cell cycle related proteins, apoptosis, and proliferation in pituitary adenomas. J Histochem Cytochem 49(9): 1193-1194, 2001.
18. Losa M, Barzaghi RL, Mortini P, Franzin A, Mangili F, Terreni MR and Giovanelli M: Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors: Comparison between micro- and macroadenomas. Am J Pathol 156(1): 245-251, 2000.
19. Sambaziotis D, Kapranos N and Kontogeorgos G: Correlation of BCL-2 and BAX with apoptosis in human pituitary adenomas. Pituitary 6(3): 127-133, 2003.
20. Green VL, White MC, Hipkin LJ, Jeffreys RV, Foy PM and Atkin SL: Apoptosis and p53 suppressor gene protein expression in human anterior pituitary adenomas. Eur J Endocrinol 36(4): 382-387, 1997.
21. Ozer E, Canda MS, Ulukus C, Guray M and Erbayraktar S: Expression of BCL-2, BAX and p53 proteins in pituitary adenomas: An immunohistochemical study. Tumori 89(1): 54-59, 2003.
22. Suzui H, Takahashi JA, Fukumoto M, Hashimoto N, Itoh N, Hatanaka M and Kikuchi H: Immunohistochemical study for basic fibroblast growth factor and fibroblast growth factor receptor I in pituitary adenomas. Neurosci Lett 171(1-2): 192-196, 1994.
23. Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young WF Jr., Meyer FB, Kuroki T, Riehle DL abd Laws ER Jr.: Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59(2): 341-353; discussion 341-353, 2006.
24. Suliman M, Royds J, Cullen D, Timperley W, Powell T, Battersby R and Jones TH: MDM2 and the p53 pathway in human pituitary adenomas. Clin Endocrinol (Oxf) 54(3): 317-325, 2001.
25. Kontogeorgos G, Kapranos N, Thodou E, Sambaziotis D and Tsagarakis S: Immunocytochemical accumulation of p53 in corticotroph adenomas: Relationship with heat-shock proteins and apoptosis. Pituitary 1(3-4): 207-212, 1999.
26. Kontogeorgos G: Predictive markers of pituitary adenoma behavior. Neuroendocrinology 83: 179-188, 2006.
27. Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ and Laws ER Jr.: p53 expression in pituitary adenomas and carcinomas: Correlation with invasiveness and tumor growth fractions. Neurosurgery 38(4): 765-770, 1996.
28. Chesnokova V, Zonis S, Kovacs K, Ben-Shlomo A, Wawrowsky K, Bannykh S and Melmed S: p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci USA 105(45): 17498-17503, 2008.
29. Melmed S: Acromegaly pathogenesis and treatment. J Clin Invest 119(11): 3189-3202, 2009.
30. KIP1 expression in endocrine and other tumors. Am J Pathol 150(2): 401-407, 1997.
31. KIP1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154(2): 313-323, 1999.
32. 1 cyclin-Cdk protein kinase activity is related to p21. Cell 15;78(1): 67-74, 1994.
33. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K and Roberts JM: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27 (Kip1)-deficient mice. Cell 85(5): 733-744, 1996.
34. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA and Koff A: Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 85(5): 721-732, 1996.
35. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY and Nakayama K: Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85(5): 707-720, 1999.
36. Klopfleisch R, and Gruber AD: Differential expression of cell cycle regulators p21, p27 and p53 in metastasizing canine mammary adenocarcinomas versus normal mammary glands. Res Vet Sci 87(1): 91-96, 2009.
37. Klopfleisch R, Schütze M and Gruber AD: Loss of p27 expression in canine mammary tumors and their metastases. Res Vet Sci 88(2): 300-303, 2010.
38. KIP1 and Ki-67 in pituitary adenomas: An investigation of marker of adenoma invasiveness. Acta Neurochir (Wien) 141(2): 187-192, 1999.
39. Ikeda H, Yoshimoto T and Shida N: Molecular analysis of p21 and p27 genes in human pituitary adenomas. Br J Cancer 76(9): 1119-1123, 1997.
40. KIP1 in pituitary tumors. J Endocrinol 157(2): 337-341, 1998.
41. Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, Harris PE, Farrell WE, Claret FX and Grossman AB: Expression of phosphorylated p27(KIP1) protein and JUN activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab 87(6): 2635-2643, 2002.
42. Champoux JJ: DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70: 369-413, 2001.
43. Rybenkov VV, Ullsberger C, Vologodskii AV and Cozzarelli NR: Simplification of DNA topology below equilibrium values by type II topoisomerases. Science 277: 690-693, 1997.
44. Capranico G, Kohn KW and Cozzarelli NR: Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acid Res 18: 6611-6619, 1990.
45. Järvinen TA, Tanner M, Rantanen V, Bärlund M, Borg A, Grénman S and Isola J: Amplification and detection of topoisomerase II alpha associate with ERB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156: 839-847, 2000.
46. Münscher A, Schmid M, Saeger W, Schreiber S and Lüdecke DK: GH-, PRL-, POMC-, beta-FSH, mRNA in gonadotroph adenomas of the pituitary by in situ hybridization in comparison with immunostaining and clinical data. Endocr Pathol 12: 171-180, 2001,
47. Vidal S, Kovacs K, Horvath E, Rotondo F, Kuroki T, Lloyd RV and Scheithauer BW: Topoisomerase II alpha expression in pituitary adenomas and carcinomas in relation to tumor behavior. Mod Pathol 15: 1205-1212, 2002.
48. Onguru O, Scheithauer BW, Kovacs K, Vidal S, Jin L, Zhang S, Ruebel KH and Lloyd RV: Analysis of Cox-2 and thromboxane synthase expression in pituitary adenomas and carcinomas. Endocr Pathol 15(1): 17-27, 2004.
49. Vidal S, Kovacs K, Bell D, Horvath E, Scheithauer BW and Lloyd RV: Cyclooxygenase-2 expression in human pituitary tumors. Cancer 97(11): 2814-2821, 2003.
50. Riss D, Jin L, Qian X, Bayliss J, Scheithauer BW, Young WF Jr, Vidal S, Kovacs K, Raz A and Lloyd RV: Differential expression of galectin-3 in pituitary tumors. Cancer Res 63(9): 2251-2255, 2003.
51. Pei L and Melmed S: Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 11(4): 433-441, 1997.
52. Heaney AP, Horwitz GA, Wang Z, Singson R and Melmed S: Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 5: 1317-1321, 1999.
53. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD and Melmed S: Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 84: 761-767, 1999.
54. Zou H, McGarry TJ, Bernal T and Kirschner MW: Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285(5426): 418-422, 1999.
55. McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA and Gittoes NJ: Vascular endothelial growth factor, its receptor KDR/FLK-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87(9): 4238-4244, 2002.
56. McCabe CJ, Khaira JS, Boelaert K, Heaney AP, Tannahill LA, Hussain S, Mitchell R, Olliff J, Sheppard MC, Franklyn JA and Gittoes NJ: Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: Relationships to clinical tumour behaviour. Clin Endocrinol (Oxf) 58(2): 141-150, 2003.
57. Chen L, Liu YS, Wang LS, Yin HG, Hou QT, Liu ZX, Chen LH and Ling F: Expression of pituitary tumor transforming gene, endostatin, and basic fibroblast growth factor mRNAs in invasive pituitary adenomas. Zhong Nan Da Xue Xue Bao Yi Xue Ba 29(6): 651-653, 666, 2004.
58. Filippella M, Galland F, Kujas M, Young J, Faggiano A, Lombardi G, Colao A, Meduri G and Chanson P: Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (Oxf) 65(4): 536-543, 2006.
59. Hunter JA, Skelly RH, Aylwin SJ, Geddes JF, Evanson J, Besser GM, Monson JP and Burrin JM: The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas. Eur J Endocrinol 148(2): 203-211, 2003.
60. Sáez C, Japón MA, Ramos-Morales F, Romero F, Segura DI, Tortolero M and Pintor-Toro JA: HPTTG is overexpressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene 18(39): 5473-5476, 1999.
61. Minematsu T, Suzuki M, Sanno N, Takekoshi S, Teramoto A and Osamura RY: PTTG overexpression is correlated with angiogenesis in human pituitary adenomas. Endocr Pathol. 17(2): 143-153, 2006.
62. Ruebel KH, Leontovich AA, Jin L, Stilling GA, Zhang H, Qian X, Nakamura N, Scheithauer BW, Kovacs K and Lloyd RV: Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression: Endocrine 29: 435-444, 2006.
63. Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV and Cusimano M: Ki-67 in pituitary neoplasms: A review Part I. Neurosurgery 65;3: 429-437, 2009.
64. Gozu Iliksu H, Bilgic B, Hazneci J, Sargin H, Erkal F, Sargin M, Sonmez B, Orbay E, Seker M, Bozbuga M and Bayindir C: Is Ki-67 index a useful labeling marker for invasion of pituitary adenomas? Turk J Endocrin Metab 4: 107-113, 2005.
65. Bottoni A, Zatelli MC, Ferracin M, Tagliati F, Piccin D, Vignali C, Calin GA, Negrini M, Croce CM and Degli Uberti EC: Identification of differentially expressed microRNAs by microarray: A possible role for microRNA genes in pituitary adenomas. J Cell Physiol 210: 370-377, 2007.
66. Gong J, Zhao Y, Abdel-Fattah R, Amos S, Xiao A, Lopes MB, Hussaini IM and Laws ER: Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas: Pituitary 11: 37-48, 2008.
67. Yamada S and Takada K: Angiogenesis in pituitary adenomas. Microsc Res Tech 60(2): 236-243, 2003.
68. Niveiro M, Aranda FI, Peiró G, Alenda C and Picó A: Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas. Hum Pathol 36(10): 1090-1095, 2005.
69. Pan LX, Chen ZP, Liu YS and Zhao JH: Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space. Hiroshima J Med Sci 53(2): 23-27, 2004.
70. Arita K, Kurisu K, Tominaga A, Sugiyama K, Eguchi K, Hama S, Yoshioka H, Yamasaki F and Kanou Y: Relationship between intratumoral hemorrhage and overexpression of vascular endothelial growth factor (VEGF). Hiroshima J Med Sci 53(2): 23-27, 2004.
71. Luchi T, Saeki N, Osato K and Yamaura A: Proliferation, vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas. Acta Neurochir (Wien) 142(12): 1345-1351, 2000.
72. Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K and Stefaneanu L: Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol 10(3): 229-235, 1999.
73. Korsisaari N, Ross J, Wu X, Kowanetz M, Pal N, Hall L, Eastham-Anderson J, Forrest WF, Van Bruggen N, Peale FV and Ferrara N: Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1. Clin Cancer Res 14(1): 249-258, 2008.
74. Jugenburg M, Kovacs K, Stefaneanu L and Scheithauer BW: Vasculature in non-tumorous hypophysis, pituitary adenomas and carcinomas: a quantitative morphologic study. Endocrinol Pathol 2: 115-124, 1995.
75. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL and Wass JA: Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome. J Endocrinology 165;(2): 475-481, 2000.
76. Vidal S, Kovacs K, Horvath E, Scheithauer BW, Kuroki T and Lloyd RV: Microvessel density in pituitary adenomas and carcinomas. Virch Arch 438;(6): 595-602, 2001.
77. Smith TG, Robbins PA and Ratcliffe PJ: The human side of hypoxia-inducible factor. Br J Haematol 141(3): 325-334, 2008.
78. Wang GL, Jiang BH, Rue EA and Semenza GL: Hypoxia-inducible factor 1 is a basic helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92(12): 5510-5514, 1995.
79. Jiang BH, Rue E, Wang GL, Roe R and Semenza GL: Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271(30): 17771-17778, 1996.
80. Benizri E, Ginouvès A and Berra E: The magic of the hypoxia-signaling cascade. Cell Mol Life Sci 65(7-8): 1133-1149, 2008.
81. Formenti F, Constantin-Teodosiu D, Emmanuel Y, Cheeseman J, Dorrington KL, Edwards LM, Humphreys SM, Lappin TR, McMullin MF, McNamara CJ, Mills W, Murphy JA, O'Connor DF, Percy MJ, Ratcliffe PJ, Smith TG, Treacy M, Frayn KN, Greenhaff PL,Karpe F, Clarke K and Robbins PA: Regulation of human metabolism by hypoxia-inducible factor. Proc Natl Acad Sci USA 107(28): 12722-12727, 2010.
82. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER and Ratcliffe PJ: The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399(6733): 271-275, 1999.
83. Semenza GL: Hydroxylation of HIF-1: Oxygen sensing at the molecular level. Physiology (Bethesda) 19(4): 176-182, 2004.
84. Wong W, Goehring AS, Kapiloff MS, Langeberg LK and Scott JD: mAKAP compartmentalizes oxygen-dependent control of HIF-1alpha. Sci Signal 1(51): ra18, 2008.
85. van Uden P, Kenneth NS and Rocha S: Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J 412(3): 477-484, 2008.
86. Bruegge K, Jelkmann W and Metzen E: Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases. Curr Med Chem 14(17): 1853-1862, 2007.
87. Hsieh MM, Linde NS, Wynter A, Metzger M, Wong C, Langsetmo I, Lin A, Smith R, Rodgers GP, Donahue RE, Klaus SJ and Tisdale JF: HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood 110(6): 2140-2147, 2007.
88. Semenza GL: Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 12(19-20): 853-859, 2007.
89. Kim K, Yoshida D and Teramoto A: Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in pituitary adenomas. Endocr Pathol 16(2): 115-121, 2005.
90. Vidal S, Horvath E, Kovacs K, Kuroki T, Lloyd RV and Scheithauer BW: Expression of hypoxia-inducible factor-1alpha (HIF-1alpha) in pituitary tumours. Histol Histopathol 18(3): 679-686, 2003.
91. Yoshida D, Kim K, Yamazaki M and Teramoto A: Expression of hypoxia-inducible factor 1alpha and cathepsin D in pituitary adenomas. Endocr Pathol 16(2): 123-131, 2005.
92. Liu W, Kunishio K, Matsumoto Y, Okada M and Nagao S: Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas. J Clin Neurosci 12(7): 791-794, 2005.
93. Hussaini IM, Trotter C, Zhao Y, Abdel-Fattah R, Amos S, Xiao A, Agi CU, Redpath GT, Fang Z, Leung GK, Lopes MB and Laws ER Jr.: Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. Am J Pathol 170(1): 356-365, 2007.
94. Kawamoto H, Kawamoto K, Mizoue T, Uozumi T, Arita K and Kurisu K: Matrix metalloproteinase-9 secretion by human pituitary adenomas detected by cell immunoblot analysis. Acta Neurochir (Wien) 138(12): 1442-1448, 1996.
95. Kawamoto H, Uozumi T, Kawamoto K, Arita K, Yano T and Hirohata T: Type IV collagenase activity and cavernous sinus invasion in human pituitary adenomas. Acta Neurochir (Wien) 138(4): 390-395, 1996.
96. Turner HE, Nagy Z, Esiri MM, Harris AL and Wass JA: Role of matrix metalloproteinase 9 in pituitary tumor behavior. J Clin Endocrinol Metab 85(8): 2931-2935, 2000.
97. Knappe UJ, Hagel C, Lisboa BW, Wilczak W, Lüdecke DK and Saeger W: Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue. Acta Neuropathol 106(5): 471-478, 2003.
98. Yamada S, Ohyama K, Taguchi M, Takeshita A, Morita K, Takano K and Sano T: A study of the correlation between morphological findings and biological activities in clinically nonfunctioning adenomas. Neurosurgery 61(3): 580-584, 2007.
99. Yokoyama S, Hirano H, Moroki K, Goto M, Imamura S and Kuratsu JI: Are nonfunctioning pituitary adenomas extending into the cavernous sinus aggressive and/or invasive? Neurosurgery 49(4): 857-862; discussion 862-853, 2001.
100. Nilsen TW: Mechanisms of microRNA-mediated gene regulation in animal cells. Trends Genet 23: 243-249, 2007.
101. Stefani G and Slack FJ: Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 9: 219-230, 2008.
102. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR and Ruvkun G: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403: 901-906, 2000.
103. Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B, Müller P, Spring J, Srinivasan A, Fishman M, Finnerty J, Corbo J, Levine M, Leahy P, Davidson E and Ruvkun G: Conservation of the sequence and temporal expression of let-7 heterochromic regulatory RNA. Nature 408: 86-89, 2000.
104. Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
105. Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell 11: 441-450, 2006.
106. Gartel AL and Kandel ES: miRNAs: Little known mediators of oncogenesis. Semin Cancer Biol 18: 103-110, 2008.
107. Calin GA and Croce CM: MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 66: 7390-7394, 2006.
108. Mao ZG, He DS, Zhou J, Yao B, Xiao WW, Chen CH, Zhu YH and Wang HJ: Differential expression of microRNAs in GH-secreting pituitary adenomas. Diagn Pathol 7(5): 79, 2010.
109. Rosenfeld MG, Briata P, Dasen J, Gleiberman AS, Kioussi C, Lin C, O'Connell SM, Ryan A, Szeto DP and Treier M: Multistep signaling and transcriptional requirements for pituitary organogenesis in vivo. Recent Prog Horm Res 55: 1-13, 2000.
110. Scully KM and Rosenfeld MG: Pituitary development: Regulatory codes in mammalian organogenesis. Science. 295(5563): 2231-2235, 2002.
111. Levy A: Stem cells, hormones and pituitary adenomas. J Neuroendocrinol 20(1): 139-140, 2008.
112. Vankelecom H: Stem cells in the postnatal pituitary? Neuroendocrinology 85(2): 110-130, 2007.
113. Vankelecom H: Non-hormonal cell types in the pituitary candidating for stem cell. Semin Cell Dev Biol 18(4): 559-570, 2007.
114. Yoshimura F, Harumiya K, Ishikawa H and Otsuka Y: Differentiation of isolated chromophobes into acidophils or basophils when transplanted into the hypophysiotrophic area of hypothalamus. Endocrinol Jpn 16(5): 531-540, 1969.
115. Almeida JPC, Sherman JH, Salvatori R and Quiñones-Hinojosa A: Pituitary stem cells: Review of the literature and current understanding. Neurosurgery 67: 770-780, 2010.
116. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-Ginard B and Anversa P: Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114(6): 763-776, 2003.
117. Rando TA: Stem cells, ageing and the quest for immortality. Nature 441(7097): 1080-1086, 2006.
118. Quinones-Hinojosa A and Chaichana K: The human subventricular zone: A source of new cells and a potential source of brain tumors. Exp Neurol 205(2): 313-324, 2007.
119. Levy A: Physiological implications of pituitary trophic activity. J Endocrinol 174(2): 147-155, 2002.
120. Borrelli E, Heyman RA, Arias C, Sawchenko PE and Evans RM. Transgenic mice with inducible dwarfism. Nature 339(6225): 538-541, 1989.
121. Nolan LA, Kavanagh E, Lightman SL and Levy A: Anterior pituitary cell population control: basal cell turnover and the effects of adrenalectomy and dexamethasone treatment. J Neuroendocrinol. 10(3):207-215, 1998.
122. Wilson DB: Distribution of 3 H-thymidine in the postnatal hypophysis of the C57BL mouse. Acta Anat (Basel) 126(2): 121-126, 1986.
123. Fauquier T, Rizzoti K, Dattani M, Lovell-Badge R and Robinson IC: SOX2-expressing progenitor cells generate all of the major cell types in the adult mouse pituitary gland. Proc Natl Acad Sci USA 105(8): 2907-2912, 2008.
124. Gleiberman AS, Michurina T, Encinas JM, Roig JL, Krasnov P, Balordi F, Fishell G, Rosenfeld MG and Enikolopov G: Genetic approaches identify adult pituitary stem cells. Proc Natl Acad Sci USA 105(17): 6332-6337, 2008.
125. Chen J, Hersmus N, Van Duppen V, Caesens P, Denef C and Vankelecom H: The adult pituitary contains a cell population displaying stem/progenitor cell and early embryonic characteristics. Endocrinology 146(9): 3985-3998, 2005.
126. Otsuka Y, Ishikawa H, Omoto T, Takasaki Y and Yoshimura F: Effect of CRF on the morphological and functional differentiation of the cultured chromophobes isolated from rat anterior pituitaries. Endocrinol Jpn 18(2): 133-153, 1971.
127. Melmed S: Mechanisms for pituitary tumorigenesis: The plastic pituitary. J Clin Invest 112(11): 1603-1618, 2003.
128. Mogi C, Miyai S, Nishimura Y, Fukuro H, Yokoyama K, Takaki A and Inoue K: Differentiation of skeletal muscle from pituitary folliculo-stellate cells and endocrine progenitor cells. Exp Cell Res. 292(2):288-294, 2004.
129. Horvath E, Kovacs K, Penz G and Ezrin C: Origin, possible function and fate of 'follicular cells' in the anterior lobe of the human pituitary. Am J Pathol 77(2): 199-212, 1974.
130. Horvath E and Kovacs K: Folliculo-stellate cells of the human pituitary: A type of adult stem cell? Ultrastruct Pathol 26: 219-228, 2002.
131. Cocchia D and Miani N: Immunocytochemical localization of the brain-specific S-100 protein in the pituitary gland of adult rat. J Neurocytol 9: 771-782, 1980.
132. Nakajima T, Yamaguchi H and Takahashi K: S-100 protein in folliculo-stellate cells of the rat anterior lobe. Brain Res 191: 523-531, 1980.
133. Velasco ME, Roessman U and Gambetti P: The presence of glial acidic protein in the human pituitary gland. J Neuropathol Exp Neurol 41: 150-163, 1982.
134. Roncaroli F, Scheithauer BW, Cenacchi G, Horvath E, Kovacs K, Lloyd RV, Abell-Aleff P, Santi M and Yates AJ: 'Spindle cell oncocytoma' of the adenohypophysis: A tumor of folliculostellate cells? Am J Surg Pathol 26: 1048-1055, 2002.
135. Allaerts W, Fluitsma DM, Hoefsmit EC, Jeucken PH, Morreau H, Bosman FT and Drexhage HA: Immunohistochemical, morphological and ultrastructural resemblance between dendritic cells and folliculo-stellate cells in normal human and rat anterior pituitaries. J Neuroendocrinol 8: 17-29, 1996.
136. Asa SL, Kovacs K, Horvath E, Losinski NE, Laszlo FA, Domokos I and Halliday WC: Human fetal adenohypophysis: electron microscopic and ultrastructural immunocytochemical analysis. Neuroendocrinology 48: 423-431, 1988.
137. Horvath E, Coire IC, Kovacs K and Smyth HS: Folliculo-stellate cells of the human pituitary as adult stem cells: Examples of their neoplastic potential. Ultrastruct Pathol 34: 133-139, 2010.
138. Horvath E, Scheithauer BW, Kovacs K and Lloyd RV: Hypothalamus and pituitary. In: Greendfield's Neuropathology, Vol 1, 7th ed. (Graham DI and Lantos PL, (eds.)) New York: Arnold, pp. 983-1051, 2002.
139. Tanase CP, Neagu M and Albulescu R: Key signaling molecules in pituitary tumors. Exp Rev of Mole Diagn 9(8): 859-877, 2009.
140. Melillo G: Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 4(9): 601-605, 2006.
141. Syed Alwi SS, Cavell BE, Telang U, Morris ME, Parry BM and Packham G: In vivo modulation of 4E binding protein 1 (4E-BP1) phosphorylation by watercress: a pilot study. Br J Nutr 104(9): 1288-1296, 2010.
142. Chu I, Hengst L and Slingerland JM: The CDK inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 8: 253-267, 2008.
143. Clayton RN and Farrell WE: Clonality of pituitary tumours: More complicated than initially envisaged? Brain Pathol 11: 313-327, 2001.
144. Vidal S, Horvath E, Syro LV, Uribe H, Cohen S and Kovacs K: Prolactin-producing pituitary adenoma associated with prolactin cell hyperplasia. Endocrinol Pathol 13: 157-165, 2002.
145. Gale RE: Evaluation of clonality in myeloid stem-cell disorders. Semin Hematol 36(4): 361-372, 1999.
146. Santarosa M and Ashworth A: Haploinsufficiency for tumor suppressor genes: When you don't need to go all the way. Biochim Biophys Acta 1654(2): 105-122, 2004.
147. Asa SL and Ezzat S: The pathogenesis of pituitary tumours. Nat Rev Cancer 2: 836-849, 2002.
148. Faglia G and Spada A: Genesis of pituitary adenomas: state of the art. J Neurooncol 54: 95-110, 2001.
149. Buch H, El-Hadd T, Bicknell J, Simpson DJ, Farrell WE and Clayton RN: Pituitary tumours are multiclonal from the outset: Evidence from a case with dural metastases. Clin Endocrinol (Oxf) 56: 817-822, 2002.
150. Boggild MD, Jenkinson S, Pistorello M, Boscaro M, Scanarini M, McTernan P, Perrett CW, Thakker RV and Clayton RN: Molecular genetic studies of sporadic pituitary tumors. J Clin Endocrinol Metab 78: 387-393, 1994.
151. Farrell WE and Clayton RN. Molecular pathogenesis of pituitary tumors. Front Neuroendocrinol 21: 174-198, 2000.
152. Lloyd RV: Molecular pathology of pituitary adenomas. J Neurooncol 54: 111-119, 2001.
153. Nam DH, Song SY, Park K, Kim MH, Suh YL, Lee JI, Kim JS, Hong SC, Shin HJ, Park K, Eoh W and Kim JH: Clinical significance of molecular genetic changes in invasive pituitary adenomas. Exp Mol Med 33: 111-116, 2001.
154. Komminoth P, Heitz PU and Kloppel G: Pathology of MEN-1: Morphology, clinicopathologic correlations and tumor development. J Int Med 243: 455-464, 1998.
155. Sandrini F, Kirschner LS, Bei T, Farmakidis C, Yasufuku- Takano J, Takano K, Prezant TR, Marx SJ, Farrell WE, Clayton RN, Groussin L, Bertherat J and Stratakis CA: PRKAR1A, one of the Carney complex genes, and its locus (17q22-24) are rarely altered in pituitary tumours outside the Carney complex. J Med Genet 39(12): e78, 2002.
156. Alexander JM: Tumor suppressor loss in pituitary tumors. Brain Pathol 11: 342-355, 2001.
157. Yu R and Melmed S: Oncogene activation in pituitary tumors. Brain Pathol 11: 328-341, 2001.
158. Karga HJ, Alexander JM, Hedley-Whyte ET, Klibanski A and Jameson JL: Ras mutations in human pituitary tumors. J Clin Endocrinol Metab 74: 914-919, 1992.
159. Suhardja A, Kovacs K and Rutka J: Genetic basis of pituitary adenoma invasiveness: A review. J Neurooncol 52: 195-204, 2001.
160. Pei L, Melmed S, Scheithauer B, Kovacs K and Prager D: HRas mutations in human pituitary carcinoma metastases. J Clin Endocrinol Metab 78: 842-846, 1994.
161. Spada A and Vallar L: G-Protein oncogenes in acromegaly. Horm Res 38: 90-93, 1992.
162. Ruebel KH, Jin L, Zhang S, Scheithauer BW and Lloyd RV: Inactivation of the p16 gene in human pituitary non-functioning tumors by hypermethylation is more common in null cell adenomas. Endocr Pathol 12: 281-289, 2001.
163. Seemann N, Kuhn D, Wrocklage C, Keyvani K, Hackl W, Buchfelder M, Fahlbusch R and Paulus W: CDKN2A/p16 inactivation is related to pituitary adenoma type and size. J Pathol 193: 491-497, 2001.
164. Simpson DJ, Fryer AA, Grossman AB, Wass JA, Pfeifer M, Kros JM, Clayton RN and Farrell WE: Cyclin D1 (CCND1) genotype is associated with tumor grade in sporadic pituitary adenomas. Carcinogenesis 22: 1801-1807, 2001.
165. Ezzat S, Zheng L, Zhu XF, Wu GE and Asa SL: Targeted expression of a human pituitary-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 109: 69-78, 2002.